EyePoint Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EyePoint Pharmaceuticals, Inc.
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Control Delivery Systems, Inc.
- Icon Bioscience, Inc.
- New pSivida, Inc.
- pSivida Corporation
- pSivida Limited